As part of our ongoing series focussing on new registrations in Australia, we have added a product review of the use of Tofacitinib citrate in patients with moderate to severe ulcerative colitis.
This review discusses the role of the JAK signalling pathway, management of ulcerative colitis, pharmacological properties, mechanism of action and major studies featuring Tofacitinib. It also provides commentary and recommendations from Dr Miles Sparrow, a gastro-enterologist who works at the IBD clinic of The Alfred Hospital, Melbourne.
Please login below to download this issue (PDF)